11,400 Shares in AtriCure, Inc. $ATRC Bought by Oregon Public Employees Retirement Fund

Oregon Public Employees Retirement Fund acquired a new position in shares of AtriCure, Inc. (NASDAQ:ATRC) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 11,400 shares of the medical device company’s stock, valued at approximately $641,000.

Several other institutional investors also recently bought and sold shares of the business. Allworth Financial LP raised its stake in shares of AtriCure by 372.8% in the 2nd quarter. Allworth Financial LP now owns 1,527 shares of the medical device company’s stock valued at $43,000 after acquiring an additional 1,204 shares during the period. Harbor Investment Advisory LLC acquired a new position in shares of AtriCure during the 2nd quarter valued at $40,000. Sterling Capital Management LLC lifted its holdings in shares of AtriCure by 841.1% during the 3rd quarter. Sterling Capital Management LLC now owns 1,647 shares of the medical device company’s stock valued at $93,000 after acquiring an additional 1,472 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new stake in AtriCure during the 2nd quarter worth $46,000. Finally, State of Wyoming boosted its position in AtriCure by 87.7% during the 1st quarter. State of Wyoming now owns 3,537 shares of the medical device company’s stock worth $101,000 after purchasing an additional 1,653 shares during the period. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

AtriCure Price Performance

ATRC stock opened at $56.26 on Wednesday. The company has a quick ratio of 3.29, a current ratio of 4.33 and a debt-to-equity ratio of 0.17. AtriCure, Inc. has a 52-week low of $25.36 and a 52-week high of $66.02. The stock’s 50 day moving average is $57.15 and its two-hundred day moving average is $38.90. The company has a market capitalization of $2.86 billion, a PE ratio of 187.54 and a beta of 1.23.

AtriCure (NASDAQ:ATRC) last released its earnings results on Tuesday, November 3rd. The medical device company reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.23. AtriCure had a return on equity of 4.01% and a net margin of 2.52%. The company had revenue of $154.45 million during the quarter, compared to analysts’ expectations of $151.05 million. Analysts predict that AtriCure, Inc. will post 0.44 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Regina Groves sold 5,313 shares of the company’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $54.22, for a total value of $288,070.86. Following the sale, the director directly owned 34,546 shares of the company’s stock, valued at $1,873,084.12. This represents a 13.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Karl Dahlquist sold 9,370 shares of the company’s stock in a transaction on Monday, August 24th. The shares were sold at an average price of $48.89, for a total transaction of $458,099.30. Following the completion of the sale, the insider directly owned 87,319 shares in the company, valued at $4,269,025.91. This represents a 9.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 39,026 shares of company stock worth $2,172,263. Insiders own 4.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Freedom Capital downgraded AtriCure from a “strong-buy” rating to a “hold” rating in a report on Friday, October 2nd. UBS Group cut AtriCure from a “buy” rating to a “sell” rating in a research note on Wednesday, October 21st. Stifel Nicolaus set a $65.00 price objective on AtriCure in a research note on Thursday, September 17th. Weiss Ratings raised AtriCure from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Finally, Needham & Company LLC increased their target price on AtriCure from $64.00 to $70.00 and gave the company a “buy” rating in a research note on Wednesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $61.80.

AtriCure Profile

AtriCure, Inc. is a medical technology company that develops and sells products for the treatment of atrial fibrillation and other conditions addressed through cardiac surgery. Its technologies are used by surgeons and other medical professionals in hospital settings. The company’s products include surgical ablation systems designed to treat irregular heart rhythms and devices for managing the left atrial appendage, a small pouch in the heart associated with stroke risk in some patients with atrial fibrillation.